var data={"title":"Methenamine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methenamine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6550?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methenamine-drug-information\" class=\"drug drug_general\">see &quot;Methenamine: Drug information&quot;</a> and <a href=\"topic.htm?path=methenamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methenamine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194204\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hiprex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194205\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mandelamine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048556\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048548\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=methenamine-drug-information\" class=\"drug drug_general\">see &quot;Methenamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Urine pH should be acidic (eg, pH &lt;5.5) for optimal efficacy. <b></b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Urinary tract infection, prophylaxis/suppression:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methenamine hippurate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: Oral: 500 to 1,000 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 1,000 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methenamine mandelate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;6 years: Oral: 50 to 75 mg/kg/day divided every 6 to 8 hours (<i>Red Book</i> [AAP 2003]); maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: Oral: 500 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 1,000 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Urinary tract infection, prophylaxis/suppression: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methenamine hippurate: Oral: 1,000 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methenamine mandelate: Oral: 1,000 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children, Adolescents and Adults: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194182\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hippurate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hiprex: 1 g [scored; contains saccharin sodium, tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hiprex: 1 g [DSC] [scored; contains tartrazine (fd&amp;c yellow #5)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as mandelate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 g, 1 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194166\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048559\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with food to minimize GI upset; patient should drink plenty of fluids to ensure adequate urine flow; administer with cranberry juice, ascorbic acid, or ammonium chloride to acidify urine; avoid intake of alkalinizing agents (sodium bicarbonate, antacids)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194199\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048558\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prophylaxis or suppression of recurrent urinary tract infections (Hippurate: FDA approved in ages &ge;6 years and adults; Mandelate: FDA approved in children, adolescents, and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194234\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hiprex&reg; may be confused with Mirapex&reg;</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methenamine may be confused with mesalamine, methazolAMIDE, methionine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Urex may be confused with Eurax&reg;, Serax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Urex: Brand name for methenamine [U.S. (discontinued)], but also the brand name for furosemide [Australia, China, Turkey]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Urex [U.S. (discontinued)] may be confused with Eurax brand name for crotamitin [U.S., Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194232\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Large doses (higher than recommended) have resulted in bladder irritation, frequent/painful micturition, albuminuria, and hematuria.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dyspepsia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Increased serum ALT (reversible), increased serum AST (reversible)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194187\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to methenamine or any component of the formulation; severe dehydration; renal impairment; severe hepatic impairment; concurrent treatment with sulfonamides  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194170\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gout: Avoid use in patients with gout; may precipitate urate crystals in urine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reversible increases in liver function tests have occurred during therapy; periodically monitor liver function, especially in patients with hepatic impairment. Contraindicated in patients with severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tartrazine: Some products may contain tartrazine, which may cause allergic reactions in certain individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use only when long-term therapy is indicated and infection has been eradicated by appropriate antimicrobial treatment. Should not be used to treat infections outside of the lower urinary tract. Doses of 8 g daily for 3 to 4 weeks may cause bladder irritation, painful and frequent micturition, albuminuria, and gross hematuria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary acidification: Use care to maintain an acid pH of the urine, especially when treating infections due to urea splitting organisms (eg, <i>Proteus</i> and strains of <i>Pseudomonas</i>); when urine acidification is contraindicated or unattainable, use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299683\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194175\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12591&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Urinary Acidifying Agents may decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Urinary Acidifying Agents may decrease the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Methenamine may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May diminish the therapeutic effect of Methenamine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May diminish the therapeutic effect of Methenamine. Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ChlorproPAMIDE: Urinary Acidifying Agents may increase the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Urinary Acidifying Agents may decrease the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: Methenamine may enhance the adverse/toxic effect of Sulfonamide Antibiotics. Specifically, the combination may result in the formation of an insoluble precipitate in the urine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194200\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Foods/diets which alkalinize urine (pH &gt;5.5) decrease therapeutic effect of methenamine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194178\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (methenamine mandelate) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194191\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies with methenamine hippurate; animal reproduction studies have not been conducted with methenamine mandelate. Methenamine crosses the placenta and distributes to amniotic fluid (Allg&eacute;n, 1979). An increased risk of adverse fetal effects has not been observed in available studies (Furness, 1975; Gordon, 1972; Heinonen, 1977). Methenamine use has been shown to interfere with urine estriol concentrations if measured via acid hydrolysis. Use of enzyme hydrolysis prevents this lab interference. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048555\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinary pH, urinalysis, urine cultures, periodic liver function tests in patients receiving hippurate salt</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194169\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Methenamine is hydrolyzed to formaldehyde and ammonia in acidic urine; formaldehyde has nonspecific bactericidal action. Other components, hippuric acid or mandelic acid, aid in maintaining urine acidity and may aid in suppressing bacteria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194186\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Readily from the GI tract; 10% to 30% of the drug will be hydrolyzed by gastric juices unless it is protected by an enteric coating </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.6 L/kg (Allg&eacute;n 1979)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hydrolyzed to formaldehyde and ammonia in the urine; ~10% to 25% in the liver </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~4 hours (Allg&eacute;n 1979)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 1 to 2 hours (Allg&eacute;n 1979)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~70% to 90% as unchanged drug) within 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194190\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Hiprex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (100): $387.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Methenamine Hippurate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (100): $209.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Methenamine Mandelate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 g (100): $88.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (100): $166.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194194\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antihydral (CH, LU);</li>\n      <li>Haiprex (DK, IS);</li>\n      <li>Hexamandin (PL);</li>\n      <li>Hipeksal (FI);</li>\n      <li>Hiprex (AE, AT, AU, BB, BF, BJ, BM, BS, BZ, CI, CR, DO, ET, FI, GB, GH, GM, GN, GT, GY, HN, JM, KE, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NO, NZ, OM, PA, PH, SC, SD, SE, SL, SN, SR, SV, TN, TT, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Mandehexan (PL);</li>\n      <li>Mandelamine (PL);</li>\n      <li>Pedipur (PL);</li>\n      <li>Reflux (NL);</li>\n      <li>Stoppot (PL);</li>\n      <li>Urotractan (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allg&eacute;n LG, Holmberg G, Persson B, et al, &quot;Biological Fate of Methenamine in Man. Absorption, Renal Excretion and Passage to Umbilical Cord Blood, Amniotic Fluid and Breast Milk,&quot; <i>Acta Obstet Gynecol Scand</i>, 1979, 58(3):287-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methenamine-pediatric-drug-information/abstract-text/484222/pubmed\" target=\"_blank\" id=\"484222\">484222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Overtuf GD, Prober DC, eds. <i>Red Book: 2003 Report of the Committee on Infectious Diseases</i>. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furness ET, McDonald PJ, and Beasley NV, &quot;Urinary Antiseptics in Asymptomatic Bacteriuria of Pregnancy,&quot; <i>N Z Med J</i>, 1975, 81(539):417-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methenamine-pediatric-drug-information/abstract-text/1099490/pubmed\" target=\"_blank\" id=\"1099490\">1099490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gordon SF, &quot;Asymptomatic Bacteriuria of Pregnancy,&quot; <i>Clinical Medicine</i>, 1972, 22-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinonen OP, Slone D, and Shapiro S, <i>Birth Defects and Drugs in Pregnancy</i>, Littleton, MA: Publishing Sciences Group, Inc, 1977.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hiprex tablet (methenamine) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; October 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Methenamine tablet [prescribing information]. Parsippany, NJ: Edenbridge Pharmaceuticals, LLC; April 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urex tablets (methenamine) [prescribing information]. Wytheville VA: Vatring Pharmaceuticals, Inc; December 2006.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12591 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F194204\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F194205\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048556\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048548\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F194182\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F194166\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048559\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F194199\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048558\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F194234\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F194232\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F194187\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F194170\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299683\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F194175\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F194200\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F194178\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F194191\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048555\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F194169\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F194186\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F194190\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F194194\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12591|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methenamine-drug-information\" class=\"drug drug_general\">Methenamine: Drug information</a></li><li><a href=\"topic.htm?path=methenamine-patient-drug-information\" class=\"drug drug_patient\">Methenamine: Patient drug information</a></li></ul></div></div>","javascript":null}